Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast
The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.